4 completed, 2 terminated. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow lenabasum: new trials by email Literature Review of lenabasum trials Research Report on lenabasum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Lenabasum 20 mg, Lenabasum 5 mg, Placebo - Dermatomyositis | Phase 3 | Completed | Corbus Pharmaceuticals Inc. | 176 | 2018-12-17 | 2022-08-16 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis Lenabasum 20 mg, Lenabasum 5 mg, Placebo - Cystic Fibrosis | Phase 2 | Completed | Corbus Pharmaceuticals Inc. | 447 | 2017-12-22 | 2023-01-18 |
| JBT-101 in Systemic Lupus Erythematosus (SLE) JBT-101, Placebo - Systemic Lupus Erythematosus, SLE | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 2017-12-21 | 2026-05-06 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule - Diffuse Cutaneous Systemic Sclerosis | Phase 3 | Terminated | Corbus Pharmaceuticals Inc. | 365 | 2017-12-18 | 2021-03-29 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis JBT-101 (lenabasum), Placebo - Cystic Fibrosis | Phase 2 | Completed | Corbus Pharmaceuticals Inc. | 85 | 2015-09-29 | 2018-04-04 |
| Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis JBT-101, Placebo - Dermatomyositis | Phase 2 | Terminated | Corbus Pharmaceuticals Inc. | 22 | 2015-06-01 | 2023-01-19 |
Cystic Fibrosis (2) · Dermatomyositis (2) · Lupus Erythematosus, Systemic (1) · Musculoskeletal Diseases (1) · Scleroderma, Diffuse (1)
Corbus Pharmaceuticals Inc. (5) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (6) · Germany (4) · Poland (4) · United Kingdom (4) · Canada (3) · Italy (3) · Spain (3) · Belgium (2) · Bulgaria (2) · Czechia (2) · France (2) · Hungary (2) · Japan (2) · Netherlands (2) · South Korea (2)
Chester V Oddis, MD (1) · Chris Denton, MD (1) · J S Elborn, M.D. (1) · J. Stuart Elborn, MD (1) · James Chmiel, M.D. (1) · James Chmiel, MD (1) · Meggan Mackay, M.D., M.S. (1) · Robert B. Zurier, M.D. (1) · Robert Spiera, MD (1) · Victoria P Werth, MD (1) · Victoria Werth, M.D. (1)
PMID 33011099, PMID 35490744, PMID 39403556, PMID 40383862
R21AR066286 (1), UM1AI110494 (1)